» Articles » PMID: 25380815

SnoN As a Novel Negative Regulator of TGF-β/Smad Signaling: a Target for Tailoring Organ Fibrosis

Overview
Date 2014 Nov 9
PMID 25380815
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

Remodeling of the extracellular matrix is beneficial during the acute wound healing stage following tissue injury. In the short term, resident fibroblasts and myofibroblasts regulate the matrix remodeling process through production of matricellular protein components that provide structural support to the damaged tissue. This process is largely governed by the transforming growth factor-β1 (TGF-β1) pathway, a critical mediator of the remodeling process. In the long term, chronic activation of the TGF-β1 pathway promotes excessive synthesis and deposition of matrix proteins, including fibrillar collagens, which ultimately leads to organ failure. SnoN (and its alternatively-spliced isoforms SnoN2, SnoA, and SnoI) is one of four members of a family of negative regulators of TGF-β1 signaling that includes Ski and functional Smad-suppressing elements on chromosomes 15 and 18. SnoN has been shown to be structurally and functionally similar to Ski and has been demonstrated to directly interact with Ski to abrogate gene expression. Despite this, little progress has been made in delineating a specific role for SnoN in the regulation of myofibroblast phenotype and function. This review outlines the current body of knowledge of what we refer to as the "Ski-Sno superfamily," with a focus on the structural and functional importance of SnoN in mediating the fibrotic response by myofibroblasts following tissue injury.

Citing Articles

LP340, a novel histone deacetylase inhibitor, decreases liver injury and fibrosis in mice: role of oxidative stress and microRNA-23a.

Samuvel D, Lemasters J, Chou C, Zhong Z Front Pharmacol. 2024; 15:1386238.

PMID: 38828459 PMC: 11140137. DOI: 10.3389/fphar.2024.1386238.


SKIL/SnoN attenuates TGF-β1/SMAD signaling-dependent collagen synthesis in hepatic fibrosis.

Chi C, Liang X, Cui T, Gao X, Liu R, Yin C Biomol Biomed. 2023; 23(6):1014-1025.

PMID: 37389959 PMC: 10655871. DOI: 10.17305/bb.2023.9000.


ESRRB Inhibits the TGFβ Signaling Pathway to Drive Cell Proliferation in Cervical Cancer.

Li Q, Zheng P Cancer Res. 2023; 83(18):3095-3114.

PMID: 37350664 PMC: 10502452. DOI: 10.1158/0008-5472.CAN-23-0067.


Bone marrow mesenchymal stem cell transplantation alleviates radiation-induced myocardial fibrosis through inhibition of the TGF-β1/Smad2/3 signaling pathway in rabbit model.

Gu J, Li H, Wei W, Sun X, Li B, Chen Y Regen Ther. 2023; 24:1-10.

PMID: 37292187 PMC: 10244902. DOI: 10.1016/j.reth.2023.04.003.


Combination Therapy of Alpha-Lipoic Acid, Gliclazide and Ramipril Protects Against Development of Diabetic Cardiomyopathy Inhibition of TGF-β/Smad Pathway.

Dugbartey G, Wonje Q, Alornyo K, Robertson L, Adams I, Boima V Front Pharmacol. 2022; 13:850542.

PMID: 35401218 PMC: 8988231. DOI: 10.3389/fphar.2022.850542.